WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S.

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and POZEN Inc.

POZEN Inc.'s (NASDAQ:POZN) PA32520 product candidate (enteric coated aspirin 325 mg with immediate release omeprazole 20 mg) may provide less upper gastrointestinal mucosal damage usually associated with higher doses of aspirin therapy, and may allow for treatment with higher doses of aspirin (up to 325 mg/daily) to maximize cardiovascular protection, according to new data presented today at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans, Louisiana.

POZEN Inc. (NASDAQ:POZN), announced today that it will release third quarter 2008 results on October 29, 2008, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. Eastern Time with a discussion by POZEN management of the earnings and business results.

POZEN Inc. (NASDAQ: POZN), today announced that the U.S.